Every SEC Form 3/4/5 on record for this filer (CIK 1240499) — 7 issuers, 20 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| VYNE | VYNE Therapeutics Inc. | Director | 2021-07-20 → 2025-12-15 | 6 | — |
| AGRX | AGILE THERAPEUTICS INC | Director | 2020-06-11 → 2024-08-26 | 6 | — |
| MNLO | Menlo Therapeutics Inc. | Director · lapsed | 2020-03-11 → 2020-08-21 | 5 | — |
| FOMX | Foamix Pharmaceuticals Ltd. | Director · lapsed | 2019-01-28 → 2020-03-11 | 3 | — |
| SNOA | Sonoma Pharmaceuticals, Inc. | Director · lapsed | 2017-03-02 → 2018-03-02 | 6 | — |
| CYTK | CYTOKINETICS INC | EVP, Finance & CFO · lapsed | 2016-02-25 → 2017-03-02 | 2 | — |
| OCLS | Oculus Innovative Sciences, Inc. | Director · lapsed | 2015-09-02 → 2016-11-30 | 6 | — |
No open-market buy or sale on record — only grants, exercises, withholding or gifts. Switch to “All forms” to see them.
3 of 7 issuers are covered and open a security page; the rest are on file here only.
